The DOI matches its Crossref record; 113 of the 114 references it cites were found in a registry or an index.
National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
Open accessAbstract
A consensus panel from the United States and Europe was convened recently to update and revise the 1997 consensus guidelines for the neuropathologic evaluation of Alzheimer's disease (AD) and other diseases of brain that are common in the elderly. The new guidelines recognize the pre‐clinical stage of AD, enhance the assessment of AD to include amyloid accumulation as well as neurofibrillary change and neuritic plaques, establish protocols for the neuropathologic assessment of Lewy body disease, vascular brain injury, hippocampal sclerosis, and TDP‐43 inclusions, and recommend standard approaches for the workup of cases and their clinico‐pathologic correlation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinically, there is a long, prodromal stage in AD prior to the irreversibly progressive decline of cognition (Hyman et al., 2012).”
From Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer’s Disease Progression (2020) · cites this paper as Hyman et al., 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The current criteria use an ABC scoring system that requires the presence of amyloid plaques and tau neurofibrillary tangles to describe the amount of AD neuropathological change ranging from none to low to intermediate to high amounts of change.”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [69]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both Aβ and paired helical filament (PHF) tau deposits are required to fulfill neuropathologic criteria for AD [105,106]”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The new NIA criteria use the same combination of NPs and Braak stage as the minimum lesion density necessary for attributing the cause of dementia to AD (39, 40).”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, the integration of these pathological assessments following the NIAA guidelines gives a classification of AD neuropathological changes of A3B3C3 [16], that can be interpreted as high, similar to other PSEN1E280A cases.”
From Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia (2022) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, the integration of these pathological assessments following the NIAA guidelines gives a classification of AD neuropathological changes of A3B3C3 [16], that can be interpreted as high, similar to other PSEN1E280A cases.”
From Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia (2022) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“The staging scheme is widely used in neuropathologic criteria for AD [69, 70].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“The most current set of criteria for the neuropathological assessment of Alzheimer’s disease termed the 2012 National Institute on Aging-Alzheimer’s Association Guidelines are based on the semi-quantitative measure of Thal Aβ amyloid phase, Braak NFT stage and CERAD neuritic plaque score, and they are applicable to patients with or without dementia [69].”
From The neuropathological diagnosis of Alzheimer's disease (2019) · cites this paper as [69]
The cited source says what the claim attributes to it.
In the citing paper
“For cases with incomplete clinical history, higher levels of AD neuropathologic change typically are correlated with greater likelihood of cognitive impairment [29].”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [29]
The cited source says what the claim attributes to it.
In the citing paper
“The shortcomings of the NIA-Reagan criteria have been recognized and a revised set of criteria are currently in press (39, 40).”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“these findings were consistent with a high degree of AD neuropathology per the National Institute on Aging-Alzheimer’s Association (NIA-AA) criteria [3–7].”
From Diagnosing the frontal variant of Alzheimer’s disease: a clinician’s yellow brick road (2017) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“By NIA-AA criteria, the findings met criteria for “high level” AD neuropathology [3–7].”
From Diagnosing the frontal variant of Alzheimer’s disease: a clinician’s yellow brick road (2017) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Finally, we noticed that the glycolysis pathway genes were maximally expressed at different points in global AD progression for each region (pathology diagnosis by ABC score)29,30.”
From Single-cell multiregion dissection of Alzheimer’s disease (2024) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“Neuropathologic diagnosis of AD was in accordance with current NIA-AA guidelines (Hyman et al., 2012; Montine et al., 2012).”
From Cholesterol and matrisome pathways dysregulated in astrocytes and microglia (2022) · cites this paper as Hyman et al., 2012
In the citing paper
“Neuropathological examination included Braak and Braak staging for plaques and tangles and diagnosis of neuropathological AD using National Institute on Aging-Reagan criteria [47].”
From Microglia facilitate loss of perineuronal nets in the Alzheimer's disease brain (2020) · cites this paper as [47]
In the citing paper
“Anti-inflammatory DAM and pro-inflammatory DAM module members overlapped (FDR < 10%) with human protein modules (M2, M4, M35, unadjusted p-values < 0.01) that were also positively associated with Braak and CERAD neuropathological grades in human AD (Fig. 9e) [58].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [58]
In the citing paper
“Neuropathology criteria for Alzheimer’s disease provide no cutoff for establishing Alzheimer’s disease diagnosis, but only define low, intermediate, or high levels of Alzheimer’s disease neuropathological change.14”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [14]
In the citing paper
“Neuropathological criteria for the diagnosis of AD were established by the National Institute on Aging–Alzheimer Association (NIA–AA)4 and were updated in 2012 to reflect the current thinking on AD pathological assessment.5,6”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [5]
In the citing paper
“Neuropathological assessment was performed by 2 authors (T.G.B. and T.J.M.) blinded to clinical and imaging results and using NIA–AA diagnostic scoring guidelines.5,40”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [5]
In the citing paper
“Furthermore, although these areas are key in early NFT accumulation in AD, isolated tau in these regions can represent B1-level NFTs, which are associated with not or low levels of ADNC.5”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [5]
In the citing paper
“Analyses from the National Alzheimer Coordinating Center pathological database have indicated that individuals with a B2 score had clinically normal result at a rate of 25.3% (34 of 134), and 41 (37.6%) of 109 people with Aβ at autopsy had a B2 score.5”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [5]
In the citing paper
“Results of this study support the hypothesis that, with a high sensitivity and moderate to high specificity, PET imaging with [18F]flortaucipir is able to identify the underlying presence of NFTs at the B3 level and a high level of ADNC per the NIA–AA criteria, consistent with a neuropathological diagnosis of AD.5”
From Positron Emission Tomography Imaging With [ 18 F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes (2020) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 4×
“zNFT stage should be determined by the method of Braak [19,20].”
InfluentialStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 2×
“From the clinical perspective, the concept of AD has evolved to include patients with milder symptoms [2], including the proposition that there is a preclinical phase of the illness [3].”
Self-citationThe Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationDiagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Self-citationMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Self-citationDeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citation
Cited by
Sorted by citations
Items 901–1,000 of 1,032
Damotte, V., van der Lee, S. J., Chouraki, V. A., Grenier‐Boley, B., Simino, J. M., Adams, H. H. H., Tosto, G., White, C. C., Terzikhan, N., Cruchaga, C., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12333 · Cited by 40
Pablo‐Fernández, E. D., Courtney, R. J., Rockliffe, A., Gentleman, S., Holton, J. L., & Warner, T. T. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12728 · Cited by 43
The Altered Anatomical Distribution of ACE2 in the Brain With Alzheimer’s Disease Pathology
Cui, H., Su, S., Cao, Y. W., Ma, C., & Qiu, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.684874 · Cited by 43
Zhang, M., Ganz, A. B., Rohde, S., Rozemuller, A. J. M., Bank, N. B., Reinders, M. J. T., Scheltens, P., Hulsman, M., Hoozemans, J. J. M., & Holstege, H. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12899 · Cited by 43
Diagnostic biomarkers in Alzheimer’s disease
Andersen, E., Casteigne, B., Chapman, W. D., Creed, A., Foster, F., Lapins, A., Shatz, R., & Sawyer, R. P. (2021) · Biomarkers in Neuropsychiatry · doi:10.1016/j.bionps.2021.100041 · Cited by 42
Huang, Y., Wang, M., Ni, H., Zhang, J., Li, A., Hu, B., Junqueira Alves, C., Wahane, S., Rios de Anda, M., Ho, L., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01664-w · Cited by 42
“These human specimens had been previously assessed for their neuropathological ‘ABC’ score: amyloid plaque score, Braak score for neurofibrillary tangles and CERAD (Consortium to Establish a Registry for AD) score for neuritic plaques density 39,40 .”
Plasma biomarkers for prediction of Alzheimer’s disease neuropathologic change
Bermudez, C. L., Graff‐Radford, J., Syrjanen, J. A., Stricker, N. H., Algeciras‐Schimnich, A., Kouri, N., Kremers, W. K., Petersen, R. C., Jack, C. R., Knopman, D. S., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02594-w · Cited by 43
Self-citationKapasi, A., Poirier, J., Hedayat, A., Scherlek, A. A., Mondal, S., Wu, T., Gibbons, J., Barnes, L. L., Bennett, D. A., Leurgans, S. E., et al. (2023) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlad086 · Cited by 48
Self-citationBernhardt, A. M., Longen, S., Trossbach, S. V., Rossi, M., Weckbecker, D., Schmidt, F., Jäck, A., Katzdobler, S., Fietzek, U. M., Weidinger, E., et al. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02853-y · Cited by 42
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 55
Self-citationConcordance Between Amyloid-PET Quantification and Real-World Visual Reads
Zeltzer, E., Schonhaut, D. R., Mundada, N. S., Blazhenets, G., Mejía, J. A., Soleimani‐Meigooni, D. N., Cho, H., Ranasinghe, K. G., Windon, C., Yadollahikhales, G., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.2218 · Cited by 42
Self-citationAbner, E. L., Neltner, J. H., Jicha, G. A., Patel, E., Anderson, S., Wilcock, D. M., Eldik, L. J. V., & Nelson, P. T. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180514 · Cited by 42
Self-citationMotor deficits in 16-month-old male and female 3xTg-AD mice
Montbrun, T. G.-D., Fertan, E., Stover, K. R., & Brown, R. E. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.09.006 · Cited by 45
Aβ Seeding as a Tool to Study Cerebral Amyloidosis and Associated Pathology
Friesen, M., & Meyer‐Luehmann, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00233 · Cited by 41
[18F]-AV-1451 binding profile in chronic traumatic encephalopathy: a postmortem case series
Marquié, M., Agüero, C., Amaral, A. C. S., Villarejo‐Galende, A., Ramanan, P., Chong, M. S. T., Saez-Calveras, N., Bennett, R. E., Verwer, E. E., Kim, S. J. W., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0808-1 · Cited by 43
Self-citationDownstream effects of polypathology on neurodegeneration of medial temporal lobe subregions
Wisse, L. E. M., Ravikumar, S., Ittyerah, R., Lim, S., Lane, J., Bedard, M. L., Xie, L., Das, S. R., Schuck, T., Grossman, M., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01225-3 · Cited by 43
Self-citationde la Vega, M. P., Giedraitis, V., Michno, W., Kilander, L., Güner, G., Zielinski, M., Löwenmark, M., Brundin, R., Danfors, T., Söderberg, L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc6184 · Cited by 40
Rodríguez, J. L., Oltmer, J., Greve, D. N., Williams, E. M., Slepneva, N., Wang, R., Champion, S., Lang-Orsini, M., Fischl, B. R., Frosch, M. P., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215567 · Cited by 44
Self-citationBiomarker A+T−: is this Alzheimer’s disease or not? A combined CSF and pathology study
Vromen, E. M., de Boer, S. C. M., Teunissen, C. E., Rozemüller, A. J. M., Sieben, A., Bjerke, M., Initiative, A. D. N., Visser, P. J., Bouwman, F. H., Engelborghs, S., et al. (2022) · Brain · doi:10.1093/brain/awac158 · Cited by 45
Thal, D. R., Ronisz, A., Tousseyn, T., Upadhaya, A. R., Balakrishnan, K., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Otto, M., Beach, T. G., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0837-9 · Cited by 44
Self-citationAngiotensin-converting enzyme 2 (ACE2) is upregulated in Alzheimer’s disease brainPreprint
Ding, Q., Shults, N. V., Harris, B. T., & Suzuki, Y. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.08.331157 · Cited by 42
Alzheimer’s as a Systems-Level Disease Involving the Interplay of Multiple Cellular Networks
Castrillo, J. I., & Oliver, S. G. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2627-5_1 · Cited by 44
Xiao, D., Wang, K., Theriault, L., Charbel, E., & Initiative, A. D. N. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15815 · Cited by 42
Yarbro, J. M., Han, X., Dasgupta, A., Yang, K., Liu, D., Shrestha, H. K., Zaman, M., Wang, Z., Yu, K., Lee, D. G., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56853-3 · Cited by 41
Arendt, T., Brückner, M. K., & Lösche, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1465-5 · Cited by 41
A platelet protein biochip rapidly detects an Alzheimer’s disease-specific phenotype
Veitinger, M., Oehler, R., Umlauf, E., Baumgartner, R., Schmidt, G. J., Gerner, C., Babeluk, R., Attems, J., Mitulović, G., Rappold, E., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1341-8 · Cited by 41
Loss of endophilin-B1 exacerbates Alzheimer’s disease pathology
Wang, D. B., Kinoshita, Y., Kinoshita, C., Uo, T., Sopher, B. L., Cudaback, E., Keene, C. D., Bilousova, T. V., Gylys, K. H., Case, A., et al. (2015) · Brain · doi:10.1093/brain/awv128 · Cited by 42
Metabolomic‐guided discovery of Alzheimer's disease biomarkers from body fluid
Ady, C. N. A. E., Lim, S. M., Teh, L. K., Salleh, M. Z., Chin, A., Tan, M. P., Poi, P. J. H., Kamaruzzaman, S. B., Majeed, A. B. A., & Ramasamy, K. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24048 · Cited by 41
Li, C., Initiative, A. D. N., Loewenstein, D., Duara, R., Cabrerizo, M., Barker, W., & Adjouadi, M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170286 · Cited by 42
Chiotis, K., Stenkrona, P., Almkvist, O., Stepanov, V., Ferreira, D., Arakawa, R., Takano, A., Westman, E., Varrone, A., Okamura, N., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4012-5 · Cited by 45
Kautzky, A., Seiger, R., Hahn, A., Fischer, P. A., Krampla, W. W., Kasper, S. F., Kovács, G. G., & Lanzenberger, R. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00406 · Cited by 41
Kirabali, T., Rigotti, S., Siccoli, A., Liebsch, F., Shobo, A., Höck, C., Nitsch, R. M., Multhaup, G., & Kulic, L. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0846-8 · Cited by 43
Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers
Camporesi, E., Lashley, T., Gobom, J., Lantero‐Rodriguez, J., Hansson, O., Zetterberg, H., Blennow, K., & Becker, B. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01119-4 · Cited by 43
Schwab, N., Wennberg, R. A., Grenier, K., Tartaglia, M. C., Tator, C. H., & Hazrati, L. (2021) · Neurology · doi:10.1212/wnl.0000000000011668 · Cited by 42
Muñoz-Castro, C., Noori, A., Magdamo, C. G., Li, Z., Marks, J. D., Frosch, M. P., Das, S., Hyman, B. T., & Serrano-Pozo, A. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02383-4 · Cited by 41
Self-citationDugger, B. N., Serrano, G. E., Sue, L. I., Walker, D. G., Adler, C. H., Shill, H. A., Sabbagh, M. N., Caviness, J. N., Hidalgo, J., Saxon‐LaBelle, M., et al. (2012) · Journal of Parkinson s Disease · doi:10.3233/jpd-2012-11073 · Cited by 42
Self-citationChronic Effects of Mild Neurotrauma: Putting the Cart Before the Horse?
Castellani, R. J., Perry, G., & Iverson, G. L. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000193 · Cited by 40
Finze, A., Biechele, G., Rauchmann, B.-S., Franzmeier, N., Palleis, C., Katzdobler, S., Weidinger, E., Guersel, S., Schuster, S., Harris, S., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02188-8 · Cited by 40
Diagnosing the frontal variant of Alzheimer’s disease: a clinician’s yellow brick road
Sawyer, R. P., Rodriguez-Porcel, F., Hagen, M., Shatz, R., & Espay, A. J. (2017) · Journal of Clinical Movement Disorders · doi:10.1186/s40734-017-0052-4 · Cited by 40
Transcriptional and post‐transcriptional regulation of β‐secretase
Tamagno, E., Guglielmotto, M., Monteleone, D., Vercelli, A., & Tabaton, M. (2012) · IUBMB Life · doi:10.1002/iub.1099 · Cited by 40
LATE-NC aggravates GVD-mediated necroptosis in Alzheimer’s disease
Koper, M. J., Tomé, S. O., Gawor, K., Belet, A., Schoor, E. V., Schaeverbeke, J. M., Vandenberghe, R. R., Vandenbulcke, M., Ghebremedhin, E., Otto, M., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01432-6 · Cited by 42
Self-citationAgrawal, S., Farfel, J. M., Arfanakis, K., Al-Harthi, L., Shull, T., Teppen, T. L., Evia, A. M., Patel, M. B., Ely, E. W., Leurgans, S. E., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01493-7 · Cited by 40
Self-citationRavikumar, S., Denning, A. E., Lim, S., Chung, E. P., Sadeghpour, N., Ittyerah, R., Wisse, L. E. M., Das, S. R., Xie, L., Robinson, J. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49205-0 · Cited by 47
Murray, P. E., Coffman, J. A., & Garcı́a-Godoy, F. (2024) · Pathogens · doi:10.3390/pathogens13121084 · Cited by 46
Arias, J. F., Brum, W. S., Salvadó, G., Therriault, J., Servaes, S., Wang, Y., Aumont, É., Rahmouni, N., Macedo, A. C., Quispialaya, K. M., et al. (2025) · Brain · doi:10.1093/brain/awaf033 · Cited by 41
DiZazzo-Miller, R., Samuel, P. S., Barnas, J. M., & Welker, K. M. (2014) · American Journal of Occupational Therapy · doi:10.5014/ajot.2014.009829 · Cited by 40
Behrouzi, R., Liu, X., Wu, D., Robinson, A., Tanaguchi-Watanabe, S., Rollinson, S. J., Shi, J., Tian, J., Hamdalla, H. H. M., Ealing, J., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0301-z · Cited by 43
Clinical Diagnosis of Alzheimer’s Disease
Khan, T. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804832-0.00002-x · Cited by 46
Tau Platelets Correlate with Regional Brain Atrophy in Patients with Alzheimer’s Disease
Slachevsky, A., Guzmán‐Martínez, L., Delgado, C., Reyes, P. A., Farias, G. A., Muñoz‐Neira, C., Bravo, E., Farías, M., Flores, P., Cristián Garrido, I., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160652 · Cited by 40
Dodge, H. H., Zhu, J. Y., Woltjer, R. L., Nelson, P. T., Bennett, D. A., Cairns, N. J., Fardo, D. W., Kaye, J. A., Erten‐Lyons, D., Mattek, N., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.11.003 · Cited by 40
Self-citationVasodilator dysfunction and oligodendrocyte dysmaturation in aging white matter
Bagi, Z. A., Brandner, D. D., Le, P., McNeal, D. W., Gong, X., Dou, H., Fulton, D. J., Beller, A., Ngyuen, T. D., Larson, E. B., et al. (2017) · Annals of Neurology · doi:10.1002/ana.25129 · Cited by 41
Self-citationRicci, G. (2019) · Behavioural Neurology · doi:10.1155/2019/8720904 · Cited by 43
Metaxas, A., Thygesen, C., Kempf, S. J., Anzalone, M., Vaitheeswaran, R., Petersen, S., Landau, A. M., Audrain, H., Teeling, J. L., Darvesh, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52357-5 · Cited by 39
APOE is a correlate of phenotypic heterogeneity in Alzheimer disease in a national cohort
Weıntraub, S., Teylan, M., Rader, B. M., Chan, K. C. G., Bollenbeck, M., Kukull, W. A., Coventry, C., Rogalski, E. J., Bigio, E. H., & Mesulam, M. M. (2019) · Neurology · doi:10.1212/wnl.0000000000008666 · Cited by 40
Self-citationSellés, M. C., Fortuna, J. T. S., Zappa-Villar, M. F., de Faria, Y. P. R., de Souza, A. S., Suemoto, C. K., Leite, R. E. P., Rodriguez, R. D., Grinberg, L. T., Reggiani, P. C., et al. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01827-y · Cited by 42
Lazić, D., Tešić, V., Jovanović, M., Brkić, M., Milanović, D., Zloković, B. V., Kanazir, S., & Perović, M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104745 · Cited by 40
Braak, H., & Del Tredici, K. (2020) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlz123 · Cited by 40
Boche, D., & Nicoll, J. A. R. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12642 · Cited by 41
Codron, P., Letournel, F., Marty, S., Renaud, L., Bodin, A. M., Duchesne, M., Verny, C., Lenaers, G., Duyckaerts, C. J., Julien, J., et al. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12646 · Cited by 40
Self-citationDenser brain capillary network with preserved pericytes in Alzheimer's disease
Fernández‐Klett, F., Brandt, L., Fernández‐Zapata, C., Abuelnor, B., Middeldorp, J., Sluijs, J. A., Curtis, M. A., Faull, R. L. M., Harris, L. W., Bahn, S., et al. (2020) · Brain Pathology · doi:10.1111/bpa.12897 · Cited by 40
Falgàs, N., Allen, I. E., Spina, S., Grant, H. E., Piña‐Escudero, S. D., Merrilees, J. J., Gearhart, R., Rosen, H. J., Kramer, J. H., Seeley, W. W., et al. (2021) · European Journal of Neurology · doi:10.1111/ene.15203 · Cited by 42
Panitch, R., Hu, J., Xia, W., Bennett, D. A., Stein, T. D., Farrer, L. A., & Jun, G. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00975-z · Cited by 39
Hyman, B. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-023749 · Cited by 39
Self-citationLiu, N., Xu, J., Liu, H., Zhang, S., Li, M., Zhou, Y., Qin, W., Li, M. J., Yu, C., & Initiative, A. D. N. (2021) · PLoS Genetics · doi:10.1371/journal.pgen.1009363 · Cited by 39
Multimodal comparisons of QSM and PET in neurodegeneration and aging
Cogswell, P. M., & Fan, A. P. (2023) · NeuroImage · doi:10.1016/j.neuroimage.2023.120068 · Cited by 38
Villain, N., & Michalon, R. (2024) · European Journal of Neurology · doi:10.1111/ene.16302 · Cited by 43
Jiang, T., Ruan, N., Luo, P., Wang, Q., Wei, X., Li, Y., Dai, Y., Li, L., Lv, J., Liu, Y., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102320 · Cited by 43
Clinical criteria for a limbic-predominant amnestic neurodegenerative syndrome
Corriveau‐Lecavalier, N., Botha, H., Graff‐Radford, J., Switzer, A. R., Przybelski, S. A., Wiste, H. J., Murray, M. E., Reichard, R. R., Dickson, D. W., Nguyen, A. T., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae183 · Cited by 47
Self-citationUnfolded Protein Response and Macroautophagy in Alzheimer’s, Parkinson’s and Prion Diseases
Milisav, I., Šuput, D., & Ribarič, S. (2015) · Molecules · doi:10.3390/molecules201219865 · Cited by 42
Kawakatsu, S., Kobayashi, R., & Hayashi, H. (2017) · Neuropathology · doi:10.1111/neup.12364 · Cited by 39
Ko, Y., Kim, S. Y., Lee, S., & Jang, C. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.02.048 · Cited by 39
Chronic Traumatic Encephalopathy in Professional American Football Players: Where Are We Now?
Tharmaratnam, T., Iskandar, M. M. A., Tabobondung, T., Tobbia, I., Gopee‐Ramanan, P., & Tabobondung, T. A. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00445 · Cited by 44
Geier, E. G., Bourdenx, M., Storm, N. J., Cochran, J. N., Sirkis, D. W., Hwang, J.-H., Bonham, L. W., Ramos, E. M., Diaz, A., Van Berlo, V., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1925-9 · Cited by 39
Li, W., Shen, Y., Tian, D., Bu, X., Zeng, F., Liu, Y.-H., Chen, Y., Yao, X., Li, H.-Y., Chen, D., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190056 · Cited by 39
Photo-oxygenation inhibits tau amyloid formation
Suzuki, T., Hori, Y., Sawazaki, T., Shimizu, Y., Nemoto, Y., Taniguchi, A., Ozawa, S., Sohma, Y., Kanai, M., & Tomita, T. (2019) · Chemical Communications · doi:10.1039/c9cc01728c · Cited by 39
Lo, A., Evans, C. D., Mancini, M., Wang, H., Shcherbinin, S., Lu, M., Natanegara, F., & Willis, B. A. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210296 · Cited by 41
Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration
Kantarci, K., Nedelska, Z., Chen, Q., Senjem, M. L., Schwarz, C. G., Gunter, J. L., Przybelski, S. A., Lesnick, T. G., Kremers, W. K., Fields, J. A., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac013 · Cited by 39
Self-citationThe VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer's disease
Krashia, P., Spoleti, E., & D’Amelio, M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1039725 · Cited by 41
Occludin deficiency with BACE1 elevation in cerebral amyloid angiopathy
Cheng, X., He, P., Yao, H., Dong, Q., Li, R., & Shen, Y. (2014) · Neurology · doi:10.1212/wnl.0000000000000403 · Cited by 39
Neuropsychological Markers of Cognitive Decline in Persons With Alzheimer Disease Neuropathology
Hassenstab, J. J., Monsell, S. E., Mock, C., Roe, C. M., Cairns, N. J., Morris, J. C., & Kukull, W. A. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000254 · Cited by 40
Self-citationBrain Tau Imaging: Food and Drug Administration Approval of 18F-Flortaucipir Injection
Mattay, V. S., Fotenos, A. F., Ganley, C. J., & Marzella, L. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.252254 · Cited by 40
Synapses, Microglia, and Lipids in Alzheimer’s Disease
Paasila, P. J., Aramideh, J. A., Sutherland, G. T., & Graeber, M. B. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.778822 · Cited by 40
Yoshida, K., Hata, Y., Ichimata, S., Okada, K., & Nishida, N. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00352-2 · Cited by 38
Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00741-9 · Cited by 42
Microstructural Bias in the Assessment of Periventricular Flow as Revealed in Postmortem Brains
Li, S., Chen, R., Cao, Z., Zhu, Q., Ma, Y., Zhu, K., Lin, Z., Wu, D., & Initiative, A. D. N. (2025) · Radiology · doi:10.1148/radiol.250753 · Cited by 39
McMillan, C. T., & Wolk, D. A. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2015-312690 · Cited by 39
Grigoletto, J., Pukaß, K., Gamliel, A., Davidi, D., Katz‐Brull, R., Richter‐Landsberg, C., & Sharon, R. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0439-3 · Cited by 42
Navarro, P. P., Genoud, C., Castaño‐Díez, D., Graff-Meyer, A., Lewis, A. J., de Gier, Y., Lauer, M. E., Britschgi, M., Bohrmann, B., Frank, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-36223-4 · Cited by 40
Spectrum of tau pathologies in Huntington's disease
Baskota, S. U., López, O. L., Greenamyre, J. T., & Kofler, J. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0166-9 · Cited by 38
Buciuc, M., Wennberg, A. M. V., Weigand, S. D., Murray, M. E., Senjem, M. L., Spychalla, A. J., Boeve, B. F., Knopman, D. S., Jack, C. R., Kantarci, K., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191040 · Cited by 38
Self-citationFacchinetti, R., Valenza, M., Bronzuoli, M. R., Menegoni, G., Ratano, P., Steardo, L., Campolongo, P., & Scuderi, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113802 · Cited by 38
Amyloid‐ β PET and CSF in an autopsy‐confirmed cohort
Reimand, J., Boon, B. D. C., Collij, L. E., Teunissen, C. E., Rozemüller, A. J. M., van Berckel, B. N. M., Scheltens, P., Ossenkoppele, R., & Bouwman, F. H. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51195 · Cited by 40
Giannini, L., Peterson, C. S., Ohm, D. T., Xie, S. X., McMillan, C. T., Raskovsky, K., Massimo, L. M., Suh, E. R., Deerlin, V. M. V., Wolk, D. A., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01129-2 · Cited by 37
Self-citationGao, Y., Liu, J., Wang, J., Liu, Y., Zeng, L., Ge, W., & Ma, C. (2022) · Brain Pathology · doi:10.1111/bpa.13047 · Cited by 35
Thrush, K., Bennett, D. A., Gaiteri, C., Horvath, S., van Dyck, C. H., Higgins‐Chen, A., & Levine, M. E. (2022) · Aging · doi:10.18632/aging.204196 · Cited by 38
Presenilin-1 Dependent Neurogenesis Regulates Hippocampal Learning and Memory
Bonds, J. A., Hirshler, Y., Bartolotti, N., Tobin, M. K., Pizzi, M. A., Marr, R. A., & Lazarov, O. (2015) · PLoS ONE · doi:10.1371/journal.pone.0131266 · Cited by 40
Patterns of Microglial Cell Activation in Alzheimer Disease and Frontotemporal Lobar Degeneration
Taipa, R., Brochado, P., Robinson, A., Reis, I., Costa, P., Mann, D. M., Melo Pires, M., & Sousa, N. (2017) · Neurodegenerative Diseases · doi:10.1159/000457127 · Cited by 37
Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years
Josephs, K. A., Weigand, S. D., & Whitwell, J. L. (2022) · Neurology · doi:10.1212/wnl.0000000000200287 · Cited by 39
α-Synuclein pathology in post-mortem retina and optic nerve is specific for α-synucleinopathies
de Ruyter, F. J. H., Morrema, T. H. J., den Haan, J., Gase, G., Twisk, J. W. R., de Boer, J. F., Scheltens, P., Bouwman, F. H., Verbraak, F. D., Rozemüller, A. J. M., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00570-5 · Cited by 37
Amyloid or tau: the chicken or the egg?
Mann, D. M. A., & Hardy, J. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1162-1 · Cited by 39
Metadata
- Authors
- Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., Nelson, P. T., Schneider, J. A., Thal, D. R., Thies, B., Trojanowski, J. Q., Vinters, H. V., & Montine, T. J.
- Affiliations
- Harvard University (US)
- National Institutes of Health (US)
- Banner Sun Health Research Institute (US)
- Northwestern University (US)
- Washington University in St. Louis (US)
- Alzheimer's Association Chicago IL USA
- Mayo Clinic (US)
- Service de Neuropathologie Raymond Escourolle Hôpital de la Salpêtriére Paris France
- University of California San Diego (US)
- SUNY Downstate Health Sciences University (US)
- University of Kentucky (US)
- Rush University Medical Center (US)
- Universität Ulm (DE)
- Alzheimer's Association (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Washington (US)
- Corresponding author
- Montine, Thomas J.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2012-01
- Volume
- 8
- Issue
- 1
- Pages
- 1-13
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC3266529
- OpenAlex
- W2143461767
- Cited by
- 3,092
- References
- 114
- Citations by year
- 2026: 214 · 2025: 285 · 2024: 286 · 2023: 233 · 2022: 260 · 2021: 327 · 2020: 247 · 2019: 228 · 2018: 206 · 2017: 190 · 2016: 170 · 2015: 161 · 2014: 118 · 2013: 115 · 2012: 46
- FWCI
- 98.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Alzheimer's Association
- Arizona Department of Health Services (211002)
- Arizona Alzheimer’s Consortium
- Deutsche Forschungsgemeinschaft (DFG TH‐624‐4‐1)
- Alzheimer Forschung Initiative (AFI #10810)
- Nancy and Buster Alvord Endowment
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Brain, Humans, Societies, Medical, United States, Consensus Development Conferences, NIH as Topic, Practice Guidelines as Topic, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
